Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

68.79B

Market cap68.79B

Price-Earnings ratio

16.16

Price-Earnings ratio16.16

Dividend yield

0.55%

Dividend yield0.55%

Average volume

778.19K

Average volume778.19K

High today

$663.10

High today$663.10

Low today

$653.31

Low today$653.31

Open price

$658.00

Open price$658.00

Volume

463.31K

Volume463.31K

52 Week high

$821.11

52 Week high$821.11

52 Week low

$541.00

52 Week low$541.00

Stock Snapshot

The current Regeneron(REGN) stock price is $656.12, with a market capitalization of 68.79B. The stock trades at a price-to-earnings (P/E) ratio of 16.16 and offers a dividend yield of 0.55%.

On 2026-07-14, Regeneron(REGN) stock moved within a range of $653.31 to $663.10. With shares now at $656.12, the stock is trading +0.4% above its intraday low and -1.1% below the session's peak.

Trading activity shows a volume of 463.31K, compared to an average daily volume of 778.19K.

Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $821.11 and a low of $541.00.

REGN News

TipRanks 5h

Regeneron’s dupilumab granted orphan drug designation

Regeneron’s (REGN) dupilumab was granted FDA orphan drug designation, according to a post on the agency’s website. TipRanks has entered a new arena in the inve...

Simply Wall St 1d

Did Disappointing Trial Data Amid Strong Dupixent and Eylea Sales Just Shift Regeneron’s Investment Narrative?

Regeneron Pharmaceuticals recently faced a setback after disappointing clinical trial results for one of its pipeline drugs, even as key products Dupixent and E...

TipRanks 2d

Regeneron: Buy Rating Reaffirmed as Analyst Trims Eylea HD Forecasts and Lowers Price Target to $856 on Pipeline-Driven Upside Potential

Analyst Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Regeneron and decreased the price target to $856.00 from $860.00. TipRanks has...

Analyst ratings

71%

of 31 ratings

Buy

71%

Hold

29%

Sell

More REGN News

TipRanks 6d

Regeneron price target lowered to $854 from $855 at Piper Sandler

Piper Sandler analyst Biren Amin lowered the firm’s price target on Regeneron (REGN) to $854 from $855 and keeps an Overweight rating on the shares. The firm up...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.